# Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

> **NCT01193244** · PHASE3 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 1560 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Orteronel
- **DRUG:** Placebo
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01193244
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-01
- **Primary completion:** 2014-01-01
- **Final completion:** 2016-04-07
- **Target enrollment:** 1560 (ACTUAL)
- **Last updated:** 2017-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01193244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01193244, "Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01193244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*